胆管肿瘤和肝细胞癌的区域化疗
Regional Chemotherapy for Biliary Tract Tumors and Hepatocellular Carcinoma.
作者信息
Mondaca Sebastian, Yarmohammadi Hooman, Kemeny Nancy E
机构信息
Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Interventional Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
出版信息
Surg Oncol Clin N Am. 2019 Oct;28(4):717-729. doi: 10.1016/j.soc.2019.06.008. Epub 2019 Aug 7.
Abstract
Locally advanced hepatocellular carcinoma and intrahepatic cholangiocarcinoma are associated with a grim prognosis. The development of highly effective systemic therapies for these tumors has been challenging; however, numerous locoregional treatment alternatives have emerged, including transarterial hepatic embolization (TAE), transarterial chemoembolization (TACE), drug-eluting bead TACE (DEB-TACE), hepatic arterial infusion chemotherapy (HAI), radioembolization, and stereotactic body radiation therapy. Although there is potential for long-term disease control for these therapies, the evidence to guide adequate patient selection and choose among different treatment alternatives is still limited. This review focuses on the rationale and data supporting TAE, TACE, DEB-TACE, and HAI in hepatobiliary cancers.
摘要
局部晚期肝细胞癌和肝内胆管癌的预后较差。开发针对这些肿瘤的高效全身治疗方法具有挑战性；然而，已经出现了多种局部区域治疗选择，包括经动脉肝栓塞术（TAE）、经动脉化疗栓塞术（TACE）、载药微球TACE（DEB-TACE）、肝动脉灌注化疗（HAI）、放射性栓塞和立体定向体部放射治疗。尽管这些疗法有可能实现长期疾病控制，但指导适当患者选择和在不同治疗方案中进行选择的证据仍然有限。本综述重点关注支持TAE、TACE、DEB-TACE和HAI用于肝胆癌治疗的理论依据和数据。
相似文献
1
Regional Chemotherapy for Biliary Tract Tumors and Hepatocellular Carcinoma.胆管肿瘤和肝细胞癌的区域化疗
Surg Oncol Clin N Am. 2019 Oct;28(4):717-729. doi: 10.1016/j.soc.2019.06.008. Epub 2019 Aug 7.
2
Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsion.肝细胞癌经动脉化疗栓塞术后的肝脏和胆道损伤：载药微球与碘油乳剂的比较
Eur Radiol. 2017 Apr;27(4):1431-1439. doi: 10.1007/s00330-016-4488-y. Epub 2016 Jul 19.
3
Role of Radioembolization for Biliary Tract and Primary Liver Cancer.放射性栓塞在胆道和原发性肝癌中的作用。
Surg Oncol Clin N Am. 2019 Oct;28(4):731-743. doi: 10.1016/j.soc.2019.07.001.
4
Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.奥沙利铂联合氟尿嘧啶肝动脉灌注化疗与经肝动脉化疗栓塞/栓塞治疗合并主门静脉癌栓的中晚期肝癌的疗效比较
Cardiovasc Intervent Radiol. 2020 Jul;43(7):996-1005. doi: 10.1007/s00270-019-02406-3. Epub 2020 Jan 23.
5
Biomarker-Driven and Molecular Targeted Therapies for Hepatobiliary Cancers.肝胆肿瘤的生物标志物驱动和分子靶向治疗。
Semin Oncol. 2018 Jun;45(3):116-123. doi: 10.1053/j.seminoncol.2018.03.002. Epub 2018 Mar 16.
6
Advances in regional chemotherapy of the liver.肝脏区域性化疗的进展。
Expert Opin Drug Deliv. 2011 Aug;8(8):1057-69. doi: 10.1517/17425247.2011.574125. Epub 2011 Apr 21.
7
Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus Y-radioembolization for hepatocellular carcinoma.荟萃分析：药物洗脱微球经动脉化疗栓塞术与钇90放射性栓塞术治疗肝细胞癌的调整间接比较
Eur Radiol. 2017 May;27(5):2031-2041. doi: 10.1007/s00330-016-4548-3. Epub 2016 Aug 25.
8
[Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma].多柔比星洗脱微球经动脉化疗栓塞术（DEB-TACE）与传统经动脉化疗栓塞术（TACE）治疗肝细胞癌的比较
Radiologia. 2011 May-Jun;53(3):246-53. doi: 10.1016/j.rx.2010.07.010. Epub 2011 Feb 4.
9
Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma.基于肝动脉的治疗方法对不可切除肝内胆管癌的疗效比较
J Surg Oncol. 2015 Feb;111(2):213-20. doi: 10.1002/jso.23781. Epub 2014 Sep 1.
10
Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study.经动脉化疗栓塞治疗肝细胞癌后肝动脉损伤：一项回顾性对照研究中药物洗脱微球与传统化疗栓塞的比较
Acta Radiol. 2017 Feb;58(2):131-139. doi: 10.1177/0284185116648501. Epub 2016 Jul 12.
引用本文的文献
1
Development and challenges in the treatment of advanced gallbladder cancer (Review).晚期胆囊癌治疗的进展与挑战（综述）
Oncol Lett. 2025 Jun 3;30(2):382. doi: 10.3892/ol.2025.15128. eCollection 2025 Aug.
2
Design of studies on neoadjuvant therapy for intrahepatic cholangiocarcinoma.肝内胆管癌新辅助治疗的研究设计
Heliyon. 2024 Dec 25;11(2):e41356. doi: 10.1016/j.heliyon.2024.e41356. eCollection 2025 Jan 30.
3
Management of intrahepatic cholangiocarcinoma: a review for clinicians.肝内胆管癌的管理：临床医生综述
Gastroenterol Rep (Oxf). 2025 Jan 26;13:goaf005. doi: 10.1093/gastro/goaf005. eCollection 2025.
4
Current research status of transarterial therapies for hepatocellular carcinoma.肝细胞癌经动脉治疗的当前研究现状
World J Gastrointest Oncol. 2024 Sep 15;16(9):3752-3760. doi: 10.4251/wjgo.v16.i9.3752.
5
Bioengineered Organoids Offer New Possibilities for Liver Cancer Studies: A Review of Key Milestones and Challenges.生物工程类器官为肝癌研究提供新可能：关键里程碑与挑战综述
Bioengineering (Basel). 2024 Apr 1;11(4):346. doi: 10.3390/bioengineering11040346.
6
Case Report: Clinical application of continuous arterial infusion chemotherapy in neoadjuvant therapy for locally advanced gastric cancer.病例报告：持续动脉灌注化疗在局部进展期胃癌新辅助治疗中的临床应用
Front Oncol. 2023 Jun 23;13:1214599. doi: 10.3389/fonc.2023.1214599. eCollection 2023.
7
Update on Locoregional Therapies for Cholangiocellular Carcinoma.胆管细胞癌局部区域治疗的最新进展
Cancers (Basel). 2023 Apr 19;15(8):2368. doi: 10.3390/cancers15082368.
8
Machine learning based on gadoxetic acid-enhanced MRI for differentiating atypical intrahepatic mass-forming cholangiocarcinoma from poorly differentiated hepatocellular carcinoma.基于钆塞酸二钠增强磁共振成像的机器学习用于鉴别非典型肝内肿块型胆管癌与低分化肝细胞癌
Abdom Radiol (NY). 2023 Aug;48(8):2525-2536. doi: 10.1007/s00261-023-03870-9. Epub 2023 May 11.
9
Classification of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma Based on Radiomic Analysis.基于放射组学分析的肝细胞癌和肝内胆管癌分类。
Comput Math Methods Med. 2022 Feb 21;2022:5334095. doi: 10.1155/2022/5334095. eCollection 2022.
10
Hepatic Arterial Infusion of Chemotherapy for Advanced Hepatobiliary Cancers: State of the Art.晚期肝胆癌的肝动脉化疗灌注：现状
Cancers (Basel). 2021 Jun 21;13(12):3091. doi: 10.3390/cancers13123091.
本文引用的文献
1
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.卡博替尼治疗晚期和进展性肝细胞癌患者。
N Engl J Med. 2018 Jul 5;379(1):54-63. doi: 10.1056/NEJMoa1717002.
2
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.帕博利珠单抗治疗索拉非尼治疗后晚期肝细胞癌患者（KEYNOTE-224）：一项非随机、开放标签的 2 期试验。
Lancet Oncol. 2018 Jul;19(7):940-952. doi: 10.1016/S1470-2045(18)30351-6. Epub 2018 Jun 3.
3
Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.肝内和肝外胆管癌的全面分子分析：干预的潜在靶点。
Clin Cancer Res. 2018 Sep 1;24(17):4154-4161. doi: 10.1158/1078-0432.CCR-18-0078. Epub 2018 May 30.
4
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.乐伐替尼与索拉非尼用于不可切除肝细胞癌患者一线治疗的比较：一项随机、III 期非劣效性试验。
Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.
5
Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.不同经动脉栓塞疗法单独或联合局部消融或辅助全身治疗对不可切除肝细胞癌的比较疗效：一项随机对照试验的网状Meta分析
PLoS One. 2017 Sep 21;12(9):e0184597. doi: 10.1371/journal.pone.0184597. eCollection 2017.
6
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma.肝细胞癌的综合与整合基因组特征分析
Cell. 2017 Jun 15;169(7):1327-1341.e23. doi: 10.1016/j.cell.2017.05.046.
7
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.纳武利尤单抗治疗晚期肝细胞癌患者（CheckMate 040）：一项开放标签、非对照、1/2 期剂量递增和扩展试验。
Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20.
8
Perioperative Hepatic Arterial Infusion Pump Chemotherapy Is Associated With Longer Survival After Resection of Colorectal Liver Metastases: A Propensity Score Analysis.围手术期肝动脉灌注泵化疗与结直肠癌肝转移切除术后更长生存期相关：一项倾向评分分析。
J Clin Oncol. 2017 Jun 10;35(17):1938-1944. doi: 10.1200/JCO.2016.71.8346. Epub 2017 Apr 20.
9
Robotic hepatic arterial infusion pump placement.机器人辅助肝动脉灌注泵置入术。
HPB (Oxford). 2017 May;19(5):429-435. doi: 10.1016/j.hpb.2016.12.015. Epub 2017 Jan 26.
10
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.regorafenib 用于索拉非尼治疗后进展的肝细胞癌患者（RESORCE）：一项随机、双盲、安慰剂对照、3 期试验。
Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6.
Zotero 插件